Eric Ehrenberg, DO
Family Medicine · Beaver Falls, PANPI 1386679934
Payments from drug & device makers
Across 594 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$1K
- AbbVie$1K
- Amgen$966
- Lilly USA, LLC$817
- Pfizer$782
- plus $3K from 33 others
What the payments were for
- Food & beverage$9,81499%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,425 |
| GSK | 73 | $1,283 |
| AbbVie(2 entities) | 81 | $1,219 |
| Amgen | 54 | $966 |
| Lilly USA, LLC | 45 | $817 |
| Pfizer | 54 | $782 |
| Boehringer Ingelheim | 46 | $693 |
| AstraZeneca | 19 | $436 |
| E.r. Squibb & Sons, L.L.C. | 15 | $255 |
| Amarin Pharma, Inc. | 16 | $224 |
| Bayer | 10 | $173 |
| Astellas Pharma US Inc | 6 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $147 |
| Sanofi Pasteur Inc. | 6 | $125 |
| Johnson & Johnson | 8 | $118 |
| Merck | 7 | $115 |
| Dynavax Technologies Corporation | 6 | $108 |
| Novartis | 7 | $102 |
| Sanofi-aventis U.S. LLC | 7 | $97 |
| Abbott | 5 | $82 |
| Phathom Pharmaceuticals, Inc. | 6 | $75 |
| Avanir Pharmaceuticals, Inc. | 3 | $54 |
| Currax Pharmaceuticals LLC | 4 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Alkermes, Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Nevro Corp. | 2 | $40 |
| Dexcom, Inc. | 3 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| UCB, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$9,932 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 206 | $222,343 |
| EliquisApixaban | 203 | $147,679 |
| OzempicSemaglutide | 107 | $145,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $63,518 |
| RybelsusSemaglutide | 33 | $55,247 |
| TradjentaLinagliptin | 57 | $53,880 |
| TrulicityDulaglutide | 35 | $50,347 |
| XareltoRivaroxaban | 63 | $47,857 |
| MounjaroTirzepatide | 26 | $28,842 |
| ProliaDenosumab | 16 | $26,926 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $26,667 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $22,150 |
| MyrbetriqMirabegron | 32 | $22,007 |
| JanuviaSitagliptin Phosphate | 50 | $20,856 |
| FarxigaDapagliflozin Propanediol | 22 | $17,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto | $693 | $295,038292 claims |
| Novo NordiskOzempic, Rybelsus | $1,425 | $200,715140 claims |
| PfizerEliquis | $782 | $147,679203 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,283 | $112,335134 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $817 | $79,18961 claims |
| Johnson & JohnsonXarelto | $118 | $47,85763 claims |
| MerckJanuvia, Janumet Xr | $115 | $28,30963 claims |
| AmgenProlia | $966 | $26,92616 claims |
| Astellas Pharma US IncMyrbetriq | $155 | $22,00732 claims |
| AstraZenecaFarxiga, Symbicort | $436 | $20,50834 claims |
| AbbVieSynthroid | $1,219 | $4,33572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Beaver Falls
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.